FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Welch David F 2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [ CYDY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
1111 MAIN STREET, SUITE 660
3. Date of Earliest Transaction (MM/DD/YYYY)
2/21/2020
(Street)
VANCOUVER, WA 98660
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  2/21/2020    M    1819672  A $0.18  7072348  I  By LLC (1)
Common Stock  2/21/2020    A    181967  A  (3) 7254315  I  By LLC (1)
Common Stock  4/1/2020    M    2259102  A $0.5  9513417  I  By LLC (1)
Common Stock                 3002202  I  By Trust (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy)  $0.3  2/21/2020    D        1000000   9/30/2019  9/30/2024  Common Stock  1000000   (3) 0  I  By LLC (1)
Warrant (Right to Buy)  $0.18  2/21/2020    A     1000000      2/20/2020  2/25/2020  Common Stock  1000000   (3) 1000000  I  By LLC (1)
Warrant (Right to Buy)  $0.3  2/21/2020    D        819672   12/23/2019  12/23/2024  Common Stock  819672   (3) 0  I  By LLC (1)
Warrant (Right to Buy)  $0.18  2/21/2020    A     819672      2/20/2020  2/25/2020  Common Stock  819672   (3) 819672  I  By LLC (1)
Warrant (Right to BuyO  $0.18  2/21/2020    M        1819672   2/20/2020  2/25/2020  Common Stock  1819672  $0  0  I  By LLC (1)
Convertible Promissory Note  $0.5  4/1/2020    M        1129551   9/30/2019  4/1/2020  Common Stock  2259102   (4) 0  I  By LLC (1)

Explanation of Responses:
(1)  The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person.
(2)  The reported securities of the Company are held by David Welch Tr Ua 03/02/2000 Welch Charitable Remainder Unitrust Agreement II (the "Trust"), for which Dr. Welch is a trustee. The reporting person disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein
(3)  On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock.
(4)  Converted amount includes accrued but unpaid interest through the date of the conversion.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Welch David F
1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660
X



Signatures
By Arian Colachis, Attorney-in-fact 6/8/2020
**Signature of Reporting Person Date
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more CytoDyn (QB) Charts.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more CytoDyn (QB) Charts.